Argos Therapeutics

Development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases.

Launch date

Jan 1997

Market cap

Enterprise valuation

Durham North Carolina (HQ)

Revenues, earnings & profits over time

USD	2015	2016
R&D budget	62.7m	38.5m

Source: Dealroom estimates

Date	Investors	Amount	Round
-	Signet Healthcare Partners	N/A	-
Jan 1997	Duke University	N/A	Spinout
Jul 2004	N/A	N/A	Series B
Feb 2005	N/A	N/A	Grant
Oct 2006	N/A	N/A	Grant
Apr 2007	N/A	N/A	Debt
May 2008	Intersouth Partners	$17.1m	Series C
Sep 2010	N/A	$4.9m	Debt
Jul 2011	N/A	$3.5m	Debt
Apr 2012	Forbion Capital Partners Intersouth Partners TVM Capital Life Science The Aurora Schools Lumira Ventures	$25.0m	Series D
Aug 2013	Intersouth Partners Pharmstandard Aurora Private Equity Triangle Venture Partners Inbio Ventures	$42.5m	Series E
Nov 2013	yet2ventures	$17.5m	Series E
Feb 2014	N/A	N/A	IPO
Sep 2014	Horizon Technology Finance Corporation	$25.0m	Post IPO Debt
Apr 2015	N/A	$10.0m	Post IPO Equity
Mar 2016	Pharmstandard Inbio Ventures	$60.0m	Post IPO Equity
Jan 2018	N/A	$1.5m	Post IPO Equity
Total Funding		CAD139m

Tech stackLearn more about the technologies and tools that this company uses.

Financials